Tumor Biology

, Volume 36, Issue 6, pp 4773–4776 | Cite as

High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients

  • Yongqing Xu
  • Xianmin Bu
  • Chaoliu Dai
  • Chao Shang
Research Article


Previous studies have shown that some microRNAs (miRs) are intensively involved in the development of hepatocellular carcinoma. We analyzed the prognostic role of serum microRNA (miR-122) levels in hepatocellular carcinoma patients using a retrospective design. MiR-122 levels in 122 hepatocellular carcinoma patients were measured, and Cox regression analysis was performed to analyze the prognostic role of miR-122 in hepatocellular carcinoma, and the hazard ratio (HR) with 95 % confidence interval (95 %CI) was used to evaluate its prognostic role. Patients with large tumor size had lower levels of serum miR-122 (P = 0.04). However, there was no significant association of serum miR-122 levels with other clinical characteristics. Kaplan-Meier method showed that there was higher overall survival rate in hepatocellular carcinoma patients with high serum miR-122 levels compared with those with low miR-122 level (P < 0.01). When using Cox regression analysis, high serum miR-122 level was independently associated with better overall survival in hepatocellular carcinoma patients (HR = 0.26; 95 %CI 0.14–0.47, P < 0.01). Subgroup analysis by gender showed that high serum miR-122 level was independently associated with better overall survival in male patients (HR = 0.08; 95 %CI 0.03–0.22, P < 0.01), but not in female patients (HR = 0.48; 95 %CI 0.18–1.32, P = 0.16). Thus, the outcomes in the analysis suggest that high serum miR-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients, and it is a good biomarker of better prognosis in patients with hepatocellular carcinoma.


Hepatocellular carcinoma miR-122 Overall survival 


Conflicts of interest



  1. 1.
    Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1–17.CrossRefPubMedGoogle Scholar
  2. 2.
    El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–75.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79–90.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Nault JC. Pathogenesis of hepatocellular carcinoma according to aetiology. Best Pract Res Clin Gastroenterol. 2014;28:937–47.CrossRefPubMedGoogle Scholar
  6. 6.
    Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Walker JJ, Johnson JA, Wild SH. Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol. 2013;1:132–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:911–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin d supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol. 2014;2:307–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Shenoy A, Blelloch RH. Regulation of microRNA function in somatic stem cell proliferation and differentiation. Nat Rev Mol Cell Biol. 2014;15:565–76.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Jasinski-Bergner S, Mandelboim O, Seliger B. The role of microRNAs in the control of innate immune response in cancer. J Natl Cancer Inst. 2014;106.Google Scholar
  15. 15.
    Zhu Z, Zhang X, Wang G, Zheng H. Role of microRNAs in hepatocellular carcinoma. Hepat Mon. 2014;14:e18672.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microrna-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198–201.CrossRefPubMedGoogle Scholar
  17. 17.
    Jopling C. Liver-specific microRNA-122: biogenesis and function. RNA Biol. 2012;9:137–42.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Waidmann O, Koberle V, Brunner F, Zeuzem S, Piiper A, Kronenberger B. Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One. 2012;7:e45652.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, et al. Microrna-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting wnt/beta-catenin pathway. Liver Int. 2012;32:752–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. Microrna-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122:2884–97.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011;6:e28486.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Thibault PA, Huys A, Dhillon P, Wilson JA. Microrna-122-dependent and -independent replication of hepatitis c virus in hep3b human hepatoma cells. Virology. 2013;436:179–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Gupta P, Cairns MJ, Saksena NK. Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J. 2014;11:64.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Li C, Wang Y, Wang S, Wu B, Hao J, Fan H, et al. Hepatitis b virus mRNA-mediated mir-122 inhibition upregulates pttg1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol. 2013;87:2193–205.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49:3442–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yongqing Xu
    • 1
  • Xianmin Bu
    • 1
  • Chaoliu Dai
    • 1
  • Chao Shang
    • 2
  1. 1.Department of Hepatobiliary and Spleen SurgeryShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Neural BiologyBasic Medical College of China Medical UniversityShenyangChina

Personalised recommendations